Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Most dividend investors chase yield and end up watching their payouts shrink or disappear. These five stocks flip that script by pairing decades of uninterrupted payments with the cash flow coverage to keep them growing.
They are way more than just GLP-1 stocks.
Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...
Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a new Science and Innovation Center in Hyderabad can support...
Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing in...
Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.
Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow
BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.
Revenue surged 10% as six growth drivers now fuel 70% of product sales.
Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen
Three household names are days away from their ex-dividend dates, and missing the cutoff by even one session means that specific cash payment goes to someone else. The clock is running on MSFT, AMGN, and MAR.
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?
During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]
Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.
Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.
Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...
The yield you chase at 52 could quietly cannibalize the very nest egg you need at 62. Before you reach for the biggest monthly payout, understand the compounding trap hiding inside each income tier.
A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year
Rapid growth across cardiovascular, bone and rare-disease medicines allowed Amgen to raise guidance despite abandoning an obesity candidate.
Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per...
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
